Holen Sie sich die Stockscreener-App
190.01
0.57%
1.07
Schlusskurs vom Vortag:
$188.94
Offen:
$190.26
24-Stunden-Volumen:
10.27M
Relative Volume:
0.62
Marktkapitalisierung:
$75.86B
Einnahmen:
$2.23B
Nettoeinkommen (Verlust:
$-3.19B
KGV:
-23.32
EPS:
-8.1462
Netto-Cashflow:
$-1.60B
1W Leistung:
-4.46%
1M Leistung:
+25.99%
6M Leistung:
+286.20%
1J Leistung:
+569.76%
1-Tages-Spanne:
$183.28
$193.72
1-Wochen-Bereich:
$183.28
$208.90
52-Wochen-Spanne:
$22.28
$208.90
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna stock after-hours at EUR 170.09: plus 0.70 percent versus the prior close - AD HOC NEWS
Moderna Stock Is Trending: What's Going On? - Benzinga
Top Healthcare Stocks To Watch TodayOctober 1st - MarketBeat
Moderna loses US government license defense in Northwestern patent case - reuters.com
Why Citi Is Sounding the Alarm on Moderna Stock - Barchart.com
Moderna Climbs 3% Despite Citigroup’s Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water - Yahoo Finance
Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water - 247wallst.com
Moderna Stock Gets Sell Call As Oncology Hopes Face Valuation Test - Simply Wall Street
The Escalator: Moderna, Hatteras Venture Partners, PhRMA and more - Medical Marketing and Media
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet - FinancialContent
Moderna adds COO role. Moderna stock falls 1.40 percent - AD HOC NEWS
Moderna, Cerebras, Jabil, HPE, Cal-Maine, Mattel, and More Stocks That Explain Today’s Market - Barron's
Moderna, Inc. Announces Management Changes - marketscreener.com
Why Moderna (MRNA) Shares Are Falling Today - Yahoo Finance
This Analyst Just Downgraded Moderna Stock. Here's Why. - Yahoo Finance
Citi Downgrades Moderna Stock, Warning $80 Billion Valuation Asks Too Much of Cancer Pipeline - Barron's
Moderna Stock Slumps as Citi Says It’s Time to Sell After 500% Rally This Year - Investopedia
Moderna Shares Reverse Weakness, Rise Over 3% After Key Trading Signal - Benzinga
Citi delivers major verdict after Moderna’s remarkable 703% run - thestreet.com
Prediction: Moderna Stock Will Soar 100% by 2030 - Yahoo Finance
Prediction: Moderna Stock Will Soar 100% by 2030 - The Motley Fool
What's Going On With Moderna Stock on Wednesday? - Benzinga
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now? - Zacks Investment Research
Moderna Tumbles as Citi Advises Selling Following 600% Rally - Bloomberg.com
Moderna (MRNA) Options Traders Turn Moderately Bearish Amid Pric - GuruFocus
Moderna (NASDAQ:MRNA) Shares Gap DownHere's Why - MarketBeat
Moderna and Fair Isaac: The Best and Worst S&P 500 Stocks for the Third Quarter - Barron's
Citi tells investors it’s time to sell Moderna after 600%-plus stock gains - MarketWatch
Moderna (MRNA) Shares Drop 6.88% Premarket After Citi Downgrade Citing Valuation Concerns - GuruFocus
Moderna Inc Stock (MRNA) Opened Down by 6.27% on Sep 30: Key Drivers Unveiled - TradingKey
Three biotech updates, including accusations of theft and and a new lobbying leader - statnews.com
Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat - Yahoo Finance
Target upgraded, Moderna downgraded: Wall Street's top analyst calls - Yahoo Finance
MRNA Stock Downgraded As Valuation Fears Eclipse Cancer Win - StocksToTrade
MRNA Stock Downgraded As Valuation Fears Clash With Trial Success - timothysykes.com
Moderna (MRNA) Shares Fall Premarket After Citi Downgrades to Se - GuruFocus
MRNA Stock Falls Premarket After Citi Downgrade: Analyst Says Valuation Looks Stretched Despite Cancer Vaccine Momentum - Yahoo Finance
Premarket movers: Micron; Boeing rises, Moderna slides - Yahoo Finance
Moderna Names Juan Andres as COO - marketscreener.com
Moderna stock slips as Citi cuts to Sell (MRNA:NASDAQ) - Seeking Alpha
Moderna: Citi says oncology optimism is priced in, cuts rating to sell - Yahoo! Finance Canada
Citi Downgrades Moderna Stock after 222% Rally, Calls Oncology Expectations “Unrealistic” - TipRanks
Moderna names Juan Andres chief operating officer - TradingView
Moderna names Juan Andres as chief operating officer - Investing.com
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology - ACCESS Newswire
Moderna, Inc. (MRNA) Adds COO; Andres Returns, Collins Retires - TradingView
Citigroup Downgrades Moderna to Sell From Neutral, Adjusts Price Target to $80 From $60 - marketscreener.com
Moderna Sets Another Fresh 52-Week High: What's Happening? - Benzinga
Bayer Advances Patent Suit Over Moderna, Pfizer Covid Vaccines - Bloomberg Law News
Moderna And Merck: The Intismeran Readout That Was Worth $86 Billion (NASDAQ:MRNA) - Seeking Alpha
Precision Trading with Moderna Inc. (MRNA) Risk Zones - Stock Traders Daily
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Moderna Inc-Aktie (MRNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hoge Stephen | President |
Sep 15 '26 |
Option Exercise |
12.21 |
76,452 |
933,479 |
1,602,310 |
| Hoge Stephen | President |
Sep 15 '26 |
Sale |
146.07 |
40,281 |
5,883,846 |
1,562,029 |
| Hoge Stephen | President |
Sep 14 '26 |
Sale |
144.13 |
40,294 |
5,807,574 |
1,525,858 |
0.05%
1.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):